Ethinylestradiol/gestodene monophasic

Drug Profile

Ethinylestradiol/gestodene monophasic

Alternative Names: Ethinylestradiol/gestodene; Femodeen; Femoden ED; Femodene; Femodene ED; Femovan; Gestodene/ethinylestradiol; Ginoden; Gynera; Gynovin; Harmonet; Meliane; Minulet; Minulette; Moneva; Myvlar

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Bayer HealthCare Pharmaceuticals Inc.; Wyeth
  • Class Alkylated estrogenic steroids; Norpregnatrienes; Norpregnenes
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pregnancy

Most Recent Events

  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer HealthCare Pharmaceuticals
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 04 Apr 2007 Berlex Inc has been acquired by Bayer HealthCare (MR 9074204)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top